On the heels of Takeda pact, PeptiDream kicks off $2.2B deal to broaden Alnylam's siRNA delivery scope
PeptiDream has more tricks up its sleeve.
Days after beefing up a CNS drug discovery deal with Takeda to the tune of $3.5 billion …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
